Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cann Group.
RELATED STOCKHEAD STORIES
News
Things you may not know about Made in Australia, and ASX stocks that manufacture right here
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Health & Biotech
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Health & Biotech
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Health & Biotech
Weed Week: Mastercard says NO to cannabis transactions, as New York becomes the happening place for weed
Health & Biotech
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Health & Biotech
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
News
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
Health & Biotech
Weed Week: BOD advances Aqua Phase acquisition with stability testing
Health & Biotech
ASX Health Stocks: Most biotechs are still chasing maiden revenue, but here’s a few healthcare stocks with strong earnings
Health & Biotech
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
Health & Biotech
There’s some very good resins why our Little Green Pharma is already leading the 2023 German invasion
Health & Biotech
Weed Week: Snoop Dogg releases Death Row Cannabis and Aussie player hits the German market
News
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ScoPo’s Powerplays: ASX healthcare sector Christmas rally runs out of puff
Health & Biotech
Weed Week: Aussie companies jostle to become the world’s supplier of medicinal cannabis
Health & Biotech
